Measuring the impact of anaesthetic drug volume during surgery

Not Applicable

Completed

• Conditions: Pancreaticoduodenectomy; Anaesthesia medications; Anaesthesiology - Anaesthetics; Surgery - Other surgery; Cancer - Pancreatic; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12620001208998
• Lead Sponsor: Department of Anaesthesia, Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2020-11-10
• Study Start: 2020-11-13
• Last Update Posted: 24 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Adult patients who underwent a pancreaticoduodenectomy between 1st January 2010 to 1st June 2020 for any indication at the Austin Hospital will be eligible. Any indication for pancreaticoduodenectomy will be considered. Both emergent and elective procedures will also be considered.

Exclusion Criteria

We will exclude the following patients:
1. Distal pancreatectomy
2. Central pancreatectomy
3. Total pancreatectomy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome will be the volume (measured in milliliters) of intravenous anaesthesia medications and infusions administered intraoperatively in adult patients undergoing pancreaticoduodenectomy. This outcome will be obtained by extracting this data from the intraoperative anaesthesia medical record. [During the intraoperative period i.e. from anaesthesia induction to completion of surgery. ]